Knuijver et al. 2021: Oral Ibogaine QTc Safety Study—What Addiction Published

Definition box

Definition: Knuijver et al. (2021) in *Addiction* (doi: 10.1111/add.15448; PMID 33620733) is a descriptive open-label observational safety study of a single oral ibogaine HCl 10 mg/kg dose in n=14 opioid-dependent patients in a Dutch university medical center after conversion to morphine sulfate. Mean maximum QTc (Fridericia) prolongation was about +95 ms (range ~29–146 ms); 50% of subjects reached QTc >500 ms; severe transient ataxia occurred in all; no torsades de pointes were observed in this small sample. This is critical cardiac teaching—and not proof of physician-supervised IV ibogaine infusion (psychoactive intravenous ibogaine). Absence of TdP in n=14 does not equal cardiac safety. Ibogaine is U.S. Schedule I and not FDA-approved.

Quotable answer (57 words)

Knuijver and colleagues’ 2021 Addiction study gave oral ibogaine 10 mg/kg to 14 opioid-dependent patients and found mean QTc prolongation near 95 milliseconds, with half exceeding 500 milliseconds, plus severe ataxia. No torsades occurred in that small sample, yet risk remains serious. This oral safety study does not prove psychoactive IV ibogaine infusion.

Why this paper-spoke exists

Knuijver 2021 is among the clearest monitored university measurements of oral ibogaine’s acute cardiac and cerebellar effects. Clinics sometimes misuse “no TdP observed” as a green light. This page keeps magnitudes, percentages, and route labels intact. Related: /blog/ibogaine-mortality-cardiac-risk · /safety-and-screening · /blog/ibogaine-ecg-pre-infusion-checklist.

What was studied

| Feature | Accurate description | |---------|----------------------| | Citation | Knuijver T. et al. *Addiction*. 2021 (e-pub; print year often listed 2022). doi 10.1111/add.15448 | | Design | Descriptive open-label observational safety study | | Setting | Psychiatry department, university medical center, Netherlands | | Population | OUD patients on opioid maintenance with failed standard abstinence attempts (n=14) | | Prep | Conversion to morphine sulfate before dosing | | Dose / route | Single oral ibogaine HCl 10 mg/kg | | Monitoring | Serial QTc, BP/HR for ≥24 h; SARA ataxia scale; delirium observation scale (DOS) |

Methods (plain language)

Patients hoping for abstinence after unsuccessful standard care were converted to morphine, then given one weight-based oral ibogaine dose in hospital. Staff repeatedly measured heart rhythm intervals (QTc), vital signs, walking/coordination (ataxia), and psychoactive/delirium-observation scores for at least a day. The study’s purpose was safety description, not a pivotal efficacy RCT.

Key findings (no hype)

As reported:

• Mean maximum QTcF prolongation ≈ 95 ms (range about 29–146 ms).
• 50% of subjects reached QTc >500 ms during observation.
• In 6/14, QTc prolongation above 450 ms lasted beyond 24 hours.
• No TdP observed in this sample.
• Bradycardia / BP decreases noted.
• Severe transient ataxia with inability to walk without support in all patients.
• Withdrawal/psychomimetic effects mostly manageable in the 24-hour window (11/14 did not return to morphine within 24 h; DOS remained below threshold as reported).

Honest reading: large QTc shifts in a supervised hospital sample are a warning, not a marketing footnote. “No TdP here” is underpowered reassurance.

Limits and confounders

| Limit | Why it matters | |-------|----------------| | n=14 | Cannot exclude rare fatal arrhythmias | | Open-label | Not efficacy RCT | | Single 10 mg/kg oral dose | Not all clinic regimens; not IV | | Morphine conversion context | Specific OUD pathway | | No TdP observed | Does not prove TdP impossible | | University resources | May exceed under-monitored retreat settings |

Later PK/PD work linked to this cohort (Knuijver et al., *J Psychopharmacol* 2024; doi 10.1177/02698811241237873) further discusses CYP2D6-related clearance variability and exposure–response ideas—queued as a separate paper-spoke in inventory batch2, not invented here as IV proof.

Route honesty: oral ≠ psychoactive IV

Knuijver dosed oral ibogaine HCl. Pharmacokinetics, peak timing, and acute ataxia patterns may differ from intravenous psychoactive delivery. Regardless, QTc biology is not a loophole: IV ibogaine infusion still requires physician supervision, ECG screening, electrolytes, and continuous monitoring culture. Support IV magnesium ≠ proof that oral QTc data are irrelevant (/blog/magnesium-ibogaine-cardiac-protocol, /blog/ibogaine-oral-vs-iv).

Cardiac / YMYL context

QTc >500 ms is a conventional red-flag threshold for TdP risk discussions. A study where half of subjects cross that line after a single oral dose is foundational YMYL content for any ibogaine webpage. Pair with mortality synthesis (/blog/ibogaine-mortality-cardiac-risk), telemetry/ACLS expectations (/blog/ibogaine-telemetry-acls-monitoring), and contraindications (/blog/ibogaine-contraindications, /blog/ibogaine-pre-existing-heart-conditions).

What this does NOT prove for IV ibogaine infusion brand

| Claim | Status | |-------|--------| | “No TdP = safe to skip ECG” | Dangerously false | | “Hospital oral study proves IV brand efficacy” | False | | “Ataxia is harmless entertainment” | False — serious fall/aspiration risk teaching | | “10 mg/kg is a consumer DIY dose” | False — research context; illegal/unapproved in U.S. | | Cite as oral cardiac risk literature? | Yes — primary teaching paper |

U.S. Schedule I / not FDA. Provisional Mexico ≠ FDA clinic (/blog/is-ibogaine-legal-us).

How to interpret “no TdP observed” without false reassurance

Torsades de pointes is uncommon even among drugs that prolong QTc; a 14-person sample can easily miss it. Responsible interpretation:

1. Magnitude matters: mean ~+95 ms is large by clinical pharmacology standards.
2. Threshold crossings matter: half above 500 ms is a population red flag, not a trivia fact.
3. Duration matters: prolongation past 24 hours in 6/14 extends the risk window beyond a short “ceremony night” mindset.
4. Ataxia compounds risk: immobility, falls, and aspiration risk stack onto arrhythmia risk.
5. Setting matters: university telemetry ≠ understaffed retreat bedrooms.

Families comparing clinics should ask for continuous ECG/telemetry plans in writing (/blog/ibogaine-telemetry-acls-monitoring, /blog/cheap-ibogaine-clinic-red-flags).

Relationship to other paper-spokes in this batch

| Paper | How it relates to Knuijver 2021 | |-------|----------------------------------| | Glue 2016 noribogaine | Controlled metabolite QTc concentration–response; different molecule/route dose | | Brown & Alper / Mash / Noller | Outcome-focused oral series—must be read *with* QTc teaching, not instead of it | | Köck 2022 / Mosca 2023 | Systematic reviews that elevate cardiotoxicity/mortality themes Knuijver quantifies | | MISTIC papers | Oral + IV Mg protocols still require cardiac humility; Mg ≠ erase QTc biology |

Do not treat any single optimistic outcome paper as a rebuttal of Knuijver’s measurements.

Soft CTA

If Knuijver numbers prompted fear or curiosity about physician-supervised IV ibogaine infusion, do not DIY and do not bargain-hunt unmonitored retreats. Start at /safety-and-screening, then /apply only after cardiac education. Mortality spoke: /blog/ibogaine-mortality-cardiac-risk.

FAQ

What is Knuijver 2021? An open-label university safety study of oral ibogaine 10 mg/kg in 14 OUD patients focusing on QTc, vitals, ataxia, and acute effects.

How much did QTc rise? Mean maximum prolongation about +95 ms; half of participants exceeded 500 ms.

Did anyone have torsades in the study? No TdP was observed in this n=14 sample—insufficient to declare cardiac safety.

Was the dose intravenous? No. Oral ibogaine HCl.

Why did everyone have ataxia? Severe transient cerebellar/ataxic effects were observed in all participants—mobility support matters.

Does this prove IV ibogaine infusion is safe or effective? No. It is oral safety description, not an IV efficacy RCT.

Should I still get screening? Yes—non-negotiable (/safety-and-screening).

Is ibogaine FDA-approved? No. Schedule I in the U.S.; not FDA-approved.

Medical disclaimer

Educational research synopsis only—not medical, psychiatric, or legal advice, and not a guarantee of outcomes. Ibogaine can prolong the QTc interval and has been associated with serious cardiac events including torsades de pointes and death in some contexts. Ibogaine is Schedule I in the United States and is not FDA-approved for any indication. Provisional Mexico programs discussed on this site are not U.S. FDA clinics. Soft CTAs: /safety-and-screening, /apply.

Knuijver 2021 is oral QTc/ataxia safety literature—not psychoactive IV ibogaine proof.

Sources (selected)

1. Knuijver T., Schellekens A., Belgers M., et al. Safety of ibogaine administration in detoxification of opioid-dependent individuals: a descriptive open-label observational study. *Addiction*. 2021. doi: 10.1111/add.15448. PMID: 33620733.
2. Glue P. et al. *Clin Pharmacol Drug Dev*. 2016. doi: 10.1002/cpdd.254. (Oral noribogaine QTc.)
3. Köck P. et al. *J Subst Abuse Treat*. 2022. doi: 10.1016/j.jsat.2021.108717.
4. Mosca A. et al. *Curr Neuropharmacol*. 2023. doi: 10.2174/1570159X21666221017085612.
5. 21 CFR 1308.11 — ibogaine Schedule I (United States).